Castle Biosciences, Inc. · NASDAQ:CSTL
Castle Biosciences — Investor Presentation (February 2024)
28 slides from Castle Biosciences's investor presentation, February 2024
Slide 1: Empowering people, informing care decisions
Empowering people, informing care decisions February 2024 ©2024 Castle Biosciences 1
Slide 2: Disclaimers: Forward-Looking Statements
Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sectio
Slide 3: Disclaimers: Financial Information; Non-GAAP Financial Measures
Disclaimers Financial Information; Non-GAAP Financial Measures In this presentation, we use the metrics of Adjusted Revenues, Adjusted Gross Margin and Adjusted EBITDA, which are non-GAAP financial measures and are not calculated in accordance with generally accepted accounting principles in the Uni
Slide 4: Improving health through innovative tests that guide patient care
OUR MISSION Improving health through innovative tests that guide patient care OUR VISION Transforming disease management by keeping people first: patients, clinicians, employees, and investors ©2024 Castle Biosciences 4
Slide 5: Proven strategy designed to drive value creation for our stakeholders
Proven strategy designed to drive value creation for our stakeholders BUILD robust clinical FOCUS evidence on best/first-in-class tests with high, unmet clinical need and significant market opportunity PENETRATE target markets to further test adoption by clinicians and payers ©2024 Castle Bioscience
Slide 6: Estimated ~$8B U.S. total addressable market for commercially available tests
Estimated ~$8B U.S. total addressable market1 for FOCUS commercially available tests ~$540M ~$820M ~$600M ~$1B ~$5B TAM TAM TAM TAM TAM GASTROENTEROLOGY Cutaneous Cutaneous Suspicious Barrett’s esophagus/ Mental health therapy MENTAL HEALTH DERMATOLOGY melanoma/ squamous cell pigmented risk of progr
Slide 7: Building evidence showing the value of our tests
Building evidence showing the value of our tests BUILD Ablation has been Studies1 show clinical New study2 shows shown to stop Randomized use of our test is our test identifies progression to EAC controlled associated with adjuvant but use is generally study shows improved melanoma radiation therapy
Slide 8: DecisionDx-Melanoma provides precise, personalized risk prediction for two critical clinical questions
DecisionDx-Melanoma provides precise, personalized risk prediction for two critical clinical questions BUILD Collaborative study with the National Cancer DecisionDx-Melanoma is the only melanoma prognostic test Institute’s SEER Program Registries is the largest real- shown to be associated with impr
Slide 9: Advancing penetration of our tests with clinicians and payers
Advancing penetration of our tests with clinicians and payers PENETRATE Expert Consensus & Reimbursement Castle Commercial Guidelines1 Strategy Playbook Total Test Report Volume • DecisionDx-Melanoma: 2023 • Increased total number of ADLTs National Society for Cutaneous to 5 by obtaining approval fr
Slide 10: Expected 2024 Catalysts
Expected 2024 Catalysts Full year impact of studies showing patients who receive 1 DecisionDx-Melanoma as part of their clinical management have improved survival compared to those who are not tested Commercial expansion in alignment with Castle principles and 2 servant leadership culture DecisionDx
Slide 11: Financials
Financials ©2024 Castle Biosciences 11
Slide 12: Well positioned for continued value creation
Well positioned for continued value creation Drive robust test volume growth Maintain strong adjusted gross margin Goal to achieve operating cash flow positivity by the end of 2025 Maintain strong balance sheet Follow disciplined capital allocation ©2024 Castle Biosciences 12
Slide 13: Drive robust test report volume and revenue growth
Drive robust test report volume and revenue growth TOTAL REVENUE BY QUARTER ($M) $66.1 TOTAL TEST VOLUME BY QUARTER $61.5 $12.8 20,284 $10.3 18,409 $50.1 16,820 $7.1 14,916 $42.0 $38.3 $6.1 12,644 $3.7 $51.2 $53.3 $43.0 $34.6 $35.9 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q4 2022 Q1 2023 Q2 2023 Q3 2
Slide 14: Maintain strong Adjusted Gross Margin
Maintain strong Adjusted Gross Margin ADJUSTED GROSS MARGIN BY QUARTER1,2 OPERATING EXPENSES BY QUARTER ($M)3 $2.2 $2.2 $2.3 $2.3 $(0.3) $0.3 $2.2 $46.8 $44.7 $44.6 $44.1 $38.4 81.3% 82.3% 74.6% 76.5% 78.0% $14.4 $13.3 $12.9 $13.0 $11.3 $9.5 $10.2 $11.1 $11.3 $12.4 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4
Slide 15: Improving operating cash flow and Adjusted EBITDA
Improving operating cash flow and Adjusted EBITDA Cash position of ~$243M1 supports growth initiatives OPERATING CASH FLOW BY QUARTER ($M) ADJUSTED EBITDA BY QUARTER ($M)3,4 $18.6 $9.4 $6.6 $5.0 $(3.8) $(6.0) $(5.3) $(10.4) $(15.1) $(25.4) Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q4 2022 Q1 2023 Q2 2
Slide 16: A disciplined approach to capital allocation
A disciplined approach to capital allocation Commercial optimization Focused R&D efforts to build evidentiary support and develop tests As a lesser priority, strategic opportunities in our current therapeutic areas ©2024 Castle Biosciences 16
Slide 17: Proven strategy designed to drive value creation for our stakeholders
Proven strategy designed to drive value creation for our stakeholders BUILD robust clinical FOCUS evidence on best/first-in-class tests with high, unmet clinical need and significant market opportunity PENETRATE target markets to further test adoption by clinicians and payers ©2024 Castle Bioscience
Slide 18: Appendix
Appendix ©2024 Castle Biosciences 18 18
Slide 19: DecisionDx-Melanoma
DERMATOLOGY DecisionDx-Melanoma Provides comprehensive, personalized, genomic tumor information to guide management for patients with cutaneous melanoma Clinical Validity, Utility and Reimbursement Demonstrated Patient Outcomes Reimbursement coverage through Medicare Demonstrated clinical validity,
Slide 20: DecisionDx-SCC
DERMATOLOGY DecisionDx-SCC Identifies the risk of metastasis in patients with squamous cell carcinoma (SCC) and one or more risk factors Clinical Validity and Utility Real-World Use Framework Demonstrated validity, Study in Clinical, Cosmetic utility and impact, backed and Investigational ~200,000 ~
Slide 21: MyPath Melanoma
DERMATOLOGY MyPath Melanoma Aids in the diagnosis and management for patients with ambiguous melanocytic lesions Clinical Validity and Utility Guideline Support Demonstrated validity, • National Comprehensive utility and impact, backed Cancer Network guidelines by 17 peer-reviewed publications demon
Slide 22: TissueCypher
GASTROENTEROLOGY TissueCypher A leading risk-stratification test designed to predict risk of progression to esophageal cancer in patients with Barrett’s esophagus Clinical Validity and Utility AGA Clinical Practice Update Demonstrated validity, Recognized by the American utility and impact, backed G
Slide 23: IDgenetix
MENTAL HEALTH IDgenetix Advanced pharmacogenomic (PGx) test designed to guide medication selection and management for patients with neuropsychiatric conditions, such as depression and anxiety Advanced PGx Easy to Use • Demonstrated clinical • 10 mental health and validity, utility and impact, backed
Slide 24: DecisionDx-UM
OPHTHALMOLOGY DecisionDx-UM The standard of care for evaluating metastatic risk in uveal melanoma Clinical Validity and Utility Standard of Care Demonstrated validity, • Utilized in approximately utility and impact, backed 80% of newly diagnosed by 25 peer-reviewed patients publications, which • Fav
Slide 25: Inflammatory Skin Disease Pipeline Program
Inflammatory Skin PIPELINE Disease Pipeline Program Inflammatory Skin Disease Pipeline program to develop a genomic test aimed at guiding systemic therapy selection for patients with moderate-to-severe atopic dermatitis (AD), psoriasis (PSO) and related conditions • New data showing the • Test resul
Slide 26: Reconciliation of Non-GAAP Financial Measures (Unaudited)
Reconciliation of Non-GAAP Financial Measures (Unaudited) The table below presents the reconciliation of adjusted revenues and adjusted gross margin, which are non-GAAP financial measures. See disclaimer slide for further information regarding the Company’s use of non-GAAP financial measures. Three
Slide 27: Reconciliation of Non-GAAP Financial Measures (Unaudited)
Reconciliation of Non-GAAP Financial Measures (Unaudited) The table below presents the reconciliation of adjusted EBITDA, which is a non-GAAP financial measure. See disclaimer slide for further information regarding the Company’s use of non-GAAP financial measures. Three months ended Dec. 31, Sep. 3
Slide 28: Thank You
Thank You ©2024 Castle Biosciences 28
Castle Biosciences — Investor Presentation (February 2024) on 6ix